newsfilter
← Latest News
GlobeNewswire·

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with